The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.
Dexcom, Inc., launched a new educational campaign for people with diabetes to help provide them with guidance about beginning their healthcare journey.1 The company teamed up with a variety of celebrities, including Nick Jonas, Lance Bass, Retta, and more to promote the campaign. The campaign is based on the results of new data that says that up to 70% of people diagnosed with diabetes don’t know where to begin their health journey. Many of these same respondents also said that diabetes has prevented them pursuing a passion or interest.
In a press release, Dexcom president and chief executive officer Kevin Sayer said, “At Dexcom, we know better health empowers us all, and I believe World Diabetes Day is the perfect time to change the perception of what’s possible. Our community of users, caregivers, and physicians have inspired us—and we hope that by delivering critical health information across our portfolio of leading glucose biosensors we’re able to do the same. As we build on our legacy of pioneering this industry, we’re committed to helping people at any age and any stage of diabetes receive the information and tools they need to discover what they’re made of.”
In the same press release, singer/actor Nick Jonas added, “A diabetes diagnosis can feel isolating. With the right support and tools, like Dexcom biosensing technology, it doesn't have to be. I'm part of a community that's living proof of what people with all types of diabetes can achieve, and this World Diabetes Day, we hope to inspire others around the world to truly discover what they're made of—and embrace their full potential to live beyond their diagnoses."
Dexcom is also involved in the production of glucose monitoring products. The company also recently announced a strategic partnership with OURA, which will combine Dexcom’s glucose biosensor technology with OURA’s Oura Ring and Oura App.2
In a press release, Dexcom executive vice president of strategy and corporate development Matt Dolan said, “Dexcom offers the most accurate glucose biosensing systems on the market that help reveal the impact of daily lifestyle choices on glucose levels and enable our users to make informed decisions about their health and overall well-being. Partnering with ŌURA gives us the opportunity to redefine the category again, integrating data from Dexcom glucose biosensors with the continuous insights and metrics measured by Oura Ring. This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition, and their glucose.”
In the same press release, Oura chief executive officer Tom Hale added, “Ninety-seven percent of Oura Members have expressed interest in understanding how the food they eat impacts their health. This partnership with Dexcom will enable us to empower our members to make informed decisions and adjust behaviors to positively impact their biometrics and long-term health. Working together, ŌURA and Dexcom will help members decide what and when to eat by surfacing correlations between activities like sleep and exercise and members’ glucose levels. And because we know that people are affected differently by the same foods and activities, guidance and insights will be personalized.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.